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Adaptive seamless phase II/III designs enable a clinical
trial to be conducted in stages with the most promising
of a number of experimental treatments selected on the
basis of data observed in the first stage to continue
along with the control treatment to the second and any
subsequent stages. The main statistical challenge in such
a design is ensuring control of the type I error rate.
Most methodology for such trials is based on the same
endpoint being used for interim and final analyses. In
some settings the primary endpoint can be observed
only after long-term follow-up. In this case it may be
desirable to use short-term endpoint data along with
any long-term data available at the interim analysis to
inform treatment selection. If short-term data are avail-
able for some patients for whom the primary endpoint
is not available, basing treatment selection on these data
may lead to inflation of the type I error rate.
This talk presents a new method [1] that allows the
use of short-term endpoint information for treatment
selection whilst controlling the overall type I error rate.
The method builds on the work of Galbraith and
Marschner [2], who proposed a method for using short-
term endpoints in interim analyses for comparison of a
single experimental treatment with a control. The
method is based on adjustment of the usual group-
sequential boundaries [3,4] to allow for monitoring of a
test statistic obtained from fitting a bivariate normal
model to the correlated short-term and long-term end-
points. The model can be fitted either using a linear
mixed model or by combining the results from separate
linear regression models for the short and long-term
data [5].
Result will be presented from a simulation study to
investigate the properties of the new method. In addi-
tion to verifying control of the type I error rate, these
results show that the use of the short-term endpoint
data can lead to an increase in power when the short
and long-term endpoints are correlated.
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